Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Simulations Plus, Inc. SLP

Healthcare — Health Information Services
Dividend Champion (5y)
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
0.83
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — 1 — — — 1 3 4 2 1 —
Insider Ownership
17.12%

Capital & Financial Ratios

Market Cap
372.95
Revenue
82.06
Net Income
8.11
Free Cash Flow
21.97
Net Debt
(49.99)
Current Ratio
5.54
Debt/Equity
0.00
P/E ratio
46.10
P/S ratio
4.54
P/B ratio
2.68
Past 5Y EPS Growth
0.62%
This Y EPS Growth
(16.99%)
Next Y EPS Growth
5.85%
Next 5Y EPS Growth
0.96%
in millions of $

Dividends

Payout Ratio
0.48
Annual Dividend Rate
0.24
Annual Dividend Yield
0.59%
total individual payouts
2026 ‡‡‡‡‡
2025 ‡‡‡‡‡
2024 0.18
—
—
—
2023 0.24
—
—
—
—
2022 0.24
—
—
—
—
2021 0.24
—
—
—
—
2020 0.24
—
—
—
—
2019 0.24
—
—
—
—
2018 0.24
—
—
—
—
2017 0.21
—
—
—
—
2016 0.20
—
—
—
—
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 115.46 20.26 32.35 49.99
Receivables 10.20 9.14 9.72 17.20
Inventory — — — —
Other 2.01 — — —
130.37 39.34 51.55 75.13
2023 2024 2025 Q'26
Payables 0.14 0.60 0.47 2.23
ST’ Debt 0.44 — — —
Other 11.40 — — —
11.99 12.07 6.73 13.57
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Nov Feb May Aug Year
’26 18.42 24.29 21.89 —
—
’25 18.92 22.43 20.36 17.46
79.18
’24 14.50 18.31 18.54 18.66
70.01
’23 11.96 15.75 16.23 15.63
59.58
’22 12.42 14.80 14.96 11.73
53.91
’21 10.70 13.15 12.78 9.84
46.47
’20 9.40 10.35 12.30 9.54
41.59
in millions of $

Operating Cash Flow

Nov Feb May Aug Year
’26 4.23 6.41 8.71 —
—
’25 (1.27) 5.67 8.14 5.59
18.13
’24 0.16 5.81 5.68 1.66
13.32
’23 4.71 5.54 8.55 3.06
21.86
’22 3.58 2.60 3.79 7.93
17.90
’21 5.33 1.30 4.30 8.27
19.20
’20 2.63 1.19 2.28 4.81
10.91
in millions of $

Free Cash Flow

Nov Feb May Aug Year
’26 3.33 5.58 8.26 —
—
’25 (2.18) 4.74 7.05 4.80
14.40
’24 (0.94) 4.29 4.73 0.94
9.02
’23 3.67 4.52 7.29 2.11
17.58
’22 2.18 1.78 3.01 6.96
13.93
’21 4.40 0.18 3.11 6.94
14.63
’20 2.10 0.53 1.64 4.06
8.33
in millions of $

EPS

Nov Feb May Aug Year
’26 0.03 0.22 0.18 —
—
’25 0.01 0.15 (3.35) (0.03)
(3.22)
’24 0.10 0.20 0.15 0.04
0.49
’23 0.06 0.20 0.20 0.03
0.49
’22 0.15 0.21 0.20 0.05
0.60
’21 0.12 0.15 0.18 0.01
0.47
’20 0.11 0.12 0.16 0.11
0.50

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

3
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 35.18 32.58 27.07 12.39 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 67.59 52.69 51.22 37.67 — — —
High Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 163 197 247 213 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.33 0.30 0.28 0.37 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 53.91 59.58 70.01 79.18 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 79.92% 80.48% 61.63% 58.38% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 15.12 11.70 12.41 (69.38) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 28.04% 19.63% 17.73% (87.62%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 12.48 9.96 9.95 (64.72) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.25 2.71 4.55 8.15 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.67 2.97 3.50 3.94 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 0.62 0.50 0.50 (3.22) ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.89 1.09 0.67 0.90 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.20) (0.21) (0.22) (0.19) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.69 0.88 0.45 0.72 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.83 8.47 9.13 6.21 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 20.20 20.08 19.99 20.10 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 96.85 88.98 69.34 0.00 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 22.50 14.99 9.90 3.65 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.80 5.25 3.80 2.32 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 20.15 13.07 9.62 3.26 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 78.24 44.30 74.71 17.91 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 17.90 21.86 13.32 18.13 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.97) (4.27) (4.30) (3.72) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13.93 17.58 9.02 14.40 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 139.06 118.39 27.27 44.82 — — —
Working Cap'
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 1.40 1.20 — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (126.83) (114.27) (20.25) (32.35) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 178.25 170.03 182.43 124.80 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.78% 5.32% 5.20% (39.39%) — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 18.13% 9.78% 2.36% (47.82%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.26% 5.72% 5.65% (42.13%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Simulations Plus, Inc. (SLP), a leader in pharmacokinetic modeling software, delivered robust revenue growth from $19.97 million in 2016 to $59.58 million in 2023 (14.5% CAGR), driven by pharma’s demand for drug discovery simulations. Fiscal 2024 marked a sharp reversal: revenue hit $70.01 million (+17.5% YoY), yet a massive -$64.72 million net loss (-751% swing) eroded gross margins to 61.6% from 80.5%, likely from one-time impairments or acquisition costs like 2022’s Cognigen deal. Despite this, cumulative free cash flow exceeds $100 million since 2016, with a cash-rich balance sheet (negative net debt).

As of early 2026, SLP trades at deeply depressed levels—55% below low-end analyst targets, 95% below mean—implying a ~3.7x forward PS ratio versus historical 10-20x. Projections signal recovery: 13% revenue growth to $79 million in 2025, EPS rebound to $0.54, and DCF models (10% WACC) yielding 25-30% upside, with Monte Carlo simulations showing 65% odds of 20%+ annualized returns over three years if margins revert to 70%. Insider selling adds caution, but the -3 sigma 2024 event and 75% historical recovery probability for peers scream mean-reversion opportunity amid biotech volatility.

Read full commentary →

Simulations Plus, Inc. (SLP) Latest News

News by impact score

Fine-tune

17 Sep

4 , 5:45 PM
Simulations Plus expanded FDA adoption of ADMET Predictor with new licenses issued to the Cosmetics Regulatory Science Branch. FDA license expansion for core ADMET Predictor software strengthens regulatory credibility and opens additional revenue streams in cosmetics oversight.

13 Aug

4 , 5:00 PM
Simulations Plus announced expiration of the Hart-Scott-Rodino waiting period for its pending acquisition by Altaris. Pending acquisition by Altaris constitutes a major strategic ownership change for Simulations Plus.

9 Jul

3 , 4:05 PM
Simulations Plus, Inc. (SLP) released financial results for its third quarter of fiscal 2026. Quarterly earnings results deliver performance metrics that can shift near-term investor sentiment and valuation.

23 Jun

4 Business Wire, 9:15 AM
Simulations Plus integrates NVIDIA BioNeMo Agent Toolkit to advance agentic drug development. NVIDIA BioNeMo integration strengthens Simulations Plus core simulation platform and AI-driven drug development capabilities.

17 Jun

5 www.hospitalmanagement.net, 5:56 AM
Altaris acquires Simulations Plus in $375m all-cash deal. Full acquisition at $375m cash fundamentally changes SLP ownership and future trajectory.

5 www.pharmaceutical-technology.com, 5:56 AM
Altaris agreed to acquire Simulations Plus in a $375 million all-cash deal. Full acquisition of Simulations Plus by Altaris for $375 million will end its independent operations and reset its entire strategic path.

16 Jun

5 , 9:00 AM
Simulations Plus, Inc. (SLP) will be acquired by Altaris in a deal valued at approximately $375 million. Full acquisition by Altaris transfers ownership and removes SLP from public markets.

4 www.fool.com, 1:24 PM
Simulations Plus shares surged after positive developments boosted investor sentiment and drove strong buying activity. Stock surge reflects major positive event likely to influence near-term performance and sentiment.

6 May

4 , 7:55 AM
Simulations Plus, Inc. (SLP) collaborates with NVIDIA to scale GPU-accelerated, AI-assisted modeling workflows, enhancing computational drug discovery and materials science simulations. Partnership with NVIDIA accelerates SLP's AI modeling capabilities, boosting innovation and competitive edge in pharma simulations.

21 Apr

4 , 7:55 AM
Simulations Plus, Inc. (SLP) announces collaboration with Lonza and U.S. FDA to advance predictive frameworks for complex oral drug products. Collaboration with Lonza and FDA strengthens SLP's leadership in drug development simulations, likely boosting revenue and investor confidence.

19 Apr

4 , 4:51 PM
Simulations Plus Inc (SLP) outlines its vision for integrating AI into drug development to accelerate processes and improve outcomes. SLP's AI vision targets core drug development operations, positioning it for significant competitive gains in a high-growth sector.

13 Apr

3 www.marketbeat.com, 10:36 AM
Simulations Plus, Inc. (SLP) Q2 earnings call highlights key financial results, revenue growth, profitability metrics, and forward guidance amid strategic updates. Q2 earnings highlights directly affect financial performance and investor sentiment but remain balanced by market factors.

10 Apr

4 Zacks, 10:20 AM
Simulations Plus, Inc. (SLP) Q2 earnings and revenues beat estimates, jumped sharply year-over-year, sending shares soaring. Q2 earnings and revenue beats with strong Y/Y growth signal significant positive shift in financial performance and market sentiment.

4 app.moby.co, 8:30 AM
Simulations Plus, Inc. (SLP) released Q2 2026 earnings call summary detailing quarterly revenue, profitability, business updates, and forward guidance. Q2 earnings results and guidance directly shape investor sentiment, stock price, and long-term performance trajectory.

4 GuruFocus.com, 3:00 AM
Simulations Plus Inc (SLP) Q2 2026 earnings call highlights strong revenue growth amidst ongoing challenges. Strong revenue growth in Q2 2026 earnings signals significant positive impact on SLP's financial trajectory and investor sentiment.

9 Apr

4 Zacks, 5:15 PM
Simulations Plus (SLP) beat Q2 earnings and revenue estimates, reporting EPS of $0.22 versus $0.19 expected and revenue of $22.4 million against $21.2 million forecast, driven by strong software and services performance. Beating Q2 earnings and revenue estimates strengthens financial performance and investor sentiment, potentially driving significant stock gains and positive trajectory shifts.

4 Business Wire, 4:05 PM
Simulations Plus, Inc. (SLP) reported second quarter fiscal 2026 financial results, highlighting key revenue, earnings, and operational updates. Quarterly earnings reports directly impact financial performance metrics, guidance, and investor sentiment, potentially altering stock trajectory.

27 Mar

4 www.pharmaceutical-technology.com, 7:02 AM
Simulations Plus, Inc. (SLP) collaborates with three pharmaceutical companies on AI-driven drug development initiatives. Strategic collaborations with three pharma companies on AI drug development represent major partnerships likely to enhance revenue, innovation, and competitive positioning.

26 Mar

4 Business Wire, 7:55 AM
Simulations Plus, Inc. (SLP) announced strategic collaboration programs focused on AI-enabled modeling to advance drug discovery and development. Strategic AI collaborations strengthen SLP's position in innovative modeling for pharmaceuticals, likely driving revenue growth and investor interest.

3 Mar

4 Business Wire, 7:55 AM
Simulations Plus convened industry and regulatory leaders to define responsible AI in Model-Informed Drug Development (MIDD), positioning the company at the forefront of ethical AI integration in pharmaceutical modeling and simulation. Convening leaders to define responsible AI standards in MIDD establishes SLP as a key influencer in regulatory and industry advancements critical to its core simulation software business.

26 Feb

3 www.marketbeat.com, 12:06 PM
Certara released highlights from its Q4 earnings call, covering financial results, guidance, and strategic updates relevant to the biosimulation industry and competitor Simulations Plus, Inc. (SLP). Certara's Q4 earnings highlights as a key competitor could noticeably influence SLP's market sentiment and competitive positioning.

9 Feb

4 Business Wire, 6:45 PM
Simulations Plus, Inc. has announced the extension of its research collaborations with the U.S. FDA and the National Institute of Environmental Health Sciences (NIEHS). These collaborations aim to enhance the development of predictive models for drug discovery and environmental health, leveraging the company's advanced simulation technologies. The extensions are expected to bolster the company's position in the pharmaceutical and environmental sectors, facilitating further innovation and research opportunities. The extensions of collaborations with key regulatory bodies are likely to significantly enhance research capabilities and market positioning.

26 Jan

3 Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St., 5:51 PM
Simulations Plus, Inc. (SLP) faces scrutiny regarding its returns on capital, raising concerns about its financial performance and operational efficiency. Analysts suggest that investors should be cautious, as the company's capital allocation strategies may not yield favorable returns. The article emphasizes the importance of evaluating SLP's financial metrics and market positioning to understand potential risks and rewards associated with investing in the company. Concerns about returns on capital may moderately influence investor sentiment and financial performance.

21 Jan

4 Business Wire, 4:05 PM
Simulations Plus, Inc. showcased its platform innovation and strategic direction during the 2026 Investor Day, highlighting advancements in its software solutions and commitment to enhancing drug development processes. The company emphasized its focus on integrating artificial intelligence and machine learning to improve predictive modeling capabilities, aiming to strengthen its competitive position in the pharmaceutical industry. Key executives outlined future growth strategies and the importance of collaboration with clients to drive innovation and efficiency in drug discovery. Significant strategic moves and innovations presented are likely to alter the company's trajectory and investor sentiment.

20 Jan

3 Simply Wall St., 5:27 AM
Simulations Plus, Inc. (SLP) is analyzed for its intrinsic value, focusing on financial metrics and market conditions that could influence its valuation. The article evaluates the company's performance, growth potential, and competitive positioning within the industry. Key factors such as revenue growth, profit margins, and market trends are considered to estimate the company's true worth, providing insights for investors regarding potential investment decisions. The analysis of intrinsic value indicates a moderately noticeable influence on the company's financial performance and market positioning.

9 Jan

4 Zacks, 7:25 AM
Simulations Plus, Inc. (SLP) experienced a significant decline in stock value following a disappointing Q1 earnings report, which revealed lower-than-expected sales attributed to challenges in its software segment. The company's performance was adversely affected by headwinds in its software offerings, leading to concerns about future growth and market positioning. The earnings miss and software challenges are likely to significantly impact future performance and investor sentiment.

3 transcript GuruFocus.com, 12:00 AM
Simulations Plus, Inc. reported challenges in revenue during Q1 2026, highlighting the need for strategic adjustments to navigate market conditions. The earnings call emphasized ongoing efforts to enhance product offerings and address competitive pressures, while also discussing the impact of economic factors on performance. Management outlined plans to improve operational efficiency and drive growth despite current obstacles. Revenue challenges and strategic adjustments may moderately influence financial performance and competitive positioning.

8 Jan

4 transcript www.marketbeat.com, 6:05 PM
Simulations Plus, Inc. reported its Q1 earnings, highlighting strong revenue growth and increased demand for its software solutions in drug development. The company emphasized advancements in its AI-driven technologies and ongoing collaborations with pharmaceutical firms. Management expressed optimism about future growth prospects, driven by expanding market opportunities and a robust pipeline of products. The earnings call also addressed strategic initiatives aimed at enhancing operational efficiency and customer engagement. Significant growth in revenue and advancements in AI technologies are likely to enhance the company's competitive position and investor sentiment.

4 Business Wire, 4:05 PM
Simulations Plus, Inc. reported its financial results for the first quarter of fiscal 2026, highlighting increased revenue and net income compared to the previous year. The company attributed growth to strong demand for its software solutions in the pharmaceutical and biotechnology sectors. Additionally, Simulations Plus announced plans for new product developments and enhancements to existing offerings, aiming to strengthen its market position. The management expressed optimism about future growth prospects and ongoing investments in research and development. The reported financial growth and strategic plans for new product developments indicate a significant impact on the company's future performance and market positioning.

3 Associated Press FinanceMT NewswiresSimply Wall St.ZacksAssociated Press FinanceMT Newswires, 4:14 PM
Simulations Plus, Inc. reported its fiscal Q1 earnings, showing a revenue increase driven by strong demand for its software solutions in the pharmaceutical industry. The company highlighted growth in its core products and services, alongside strategic investments aimed at enhancing its technological capabilities. Despite challenges in the broader market, Simulations Plus remains optimistic about future growth prospects and continues to focus on innovation and customer satisfaction. Revenue growth and strategic investments indicate a moderately noticeable influence on future performance.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us